Founder Ron Cohen Number of employees 328 CEO Ron Cohen | Founded 1995 (1995) Revenue 292.2 million USD (2011) | |
 | ||
Traded as NASDAQ: ACORS&P 600 ComponentFWB: CDG Industry Health careBiotechnology Key people Ron Cohen (CEO)Andrew R. Blight Stock price ACOR (NASDAQ) US$ 26.45 -0.95 (-3.47%)28 Feb, 4:00 PM GMT-5 - Disclaimer | ||
Acorda therapeutics inc 2014 small business award
Acorda Therapeutics is a biotechnology company based in Ardsley, New York, USA. The company develops drugs to improve therapies that improve neurological function in people with multiple sclerosis, spinal cord injury and other disorders of the central nervous system. Acorda manufactures and markets the drugs Zanaflex, Ampyra and Qutenza in the United States.
Contents
- Acorda therapeutics inc 2014 small business award
- Acorda therapeutics ceo high powered biotech mad money cnbc
- History
- Corporate governance
- Products on the market
- Products under development
- References
Acorda therapeutics ceo high powered biotech mad money cnbc
History
In September 2014 the company acquired Civitas Therapeutics for $525 million - gaining the Phase III Parkinson’s drug, CVT-301.
In January 2016, the company acquired Finnish pharmaceutical company, Biotie Therapies, for $363 million. This gave the company control over Biotes sclerosing cholangitis drug, BTT1023.
In November 2016, Acorda Therapeutics announced it was discontinuing development of dalfampridine, a drug intended for post-stroke walking difficulties, after a clinical trial failure. The discontinuation of the drug caused Acorda's shares to drop as much as 13.2%. Acorda shares have dropped 50.2% since January 2016.
Corporate governance
As of December 31, 2013, the members of the board of directors of Acorda Therapeutics were: Ron Cohen, Barry Greene, Peder K. Jensen, John P. Kelley, Sandra Panem, Lorin J. Randall, Steven M. Rauscher, and Ian F. Smith.